BioMarin Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
BioMarin Pharmaceutical has a total shareholder equity of $5.8B and total debt of $595.7M, which brings its debt-to-equity ratio to 10.3%. Its total assets and total liabilities are $7.1B and $1.4B respectively. BioMarin Pharmaceutical's EBIT is $715.5M making its interest coverage ratio -11.4. It has cash and short-term investments of $1.3B.
Key information
10.3%
Debt to equity ratio
US$595.65m
Debt
| Interest coverage ratio | -11.4x |
| Cash | US$1.27b |
| Equity | US$5.79b |
| Total liabilities | US$1.35b |
| Total assets | US$7.15b |
Recent financial health updates
Is BioMarin Pharmaceutical (NASDAQ:BMRN) A Risky Investment?
Apr 27
Does BioMarin Pharmaceutical (NASDAQ:BMRN) Have A Healthy Balance Sheet?
Dec 26BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly
Sep 21Recent updates
Is BioMarin Pharmaceutical (NASDAQ:BMRN) A Risky Investment?
Apr 27The Price Is Right For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Mar 31The Strong Earnings Posted By BioMarin Pharmaceutical (NASDAQ:BMRN) Are A Good Indication Of The Strength Of The Business
Mar 04BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Feb 21BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy
Jan 23Does BioMarin Pharmaceutical (NASDAQ:BMRN) Have A Healthy Balance Sheet?
Dec 26Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call
Nov 21BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Not Flying Under The Radar
Nov 14BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly
Sep 21BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024
Aug 21BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024
Jul 24An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued
Jun 01BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain
May 15BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth
Feb 29BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?
Jan 19Financial Position Analysis
Short Term Liabilities: BMRN's short term assets ($3.5B) exceed its short term liabilities ($628.2M).
Long Term Liabilities: BMRN's short term assets ($3.5B) exceed its long term liabilities ($725.3M).
Debt to Equity History and Analysis
Debt Level: BMRN has more cash than its total debt.
Reducing Debt: BMRN's debt to equity ratio has reduced from 26.3% to 10.3% over the past 5 years.
Debt Coverage: BMRN's debt is well covered by operating cash flow (117.6%).
Interest Coverage: BMRN earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 07:52 |
| End of Day Share Price | 2025/05/05 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioMarin Pharmaceutical Inc. is covered by 56 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Ishan Majumdar | Baptista Research |
| Ying Huang | Barclays |